Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Over 21 days of talking with ChatGPT, an otherwise perfectly sane man became convinced that he was a real-life superhero. We analyzed the conversation. By Kashmir Hill and Dylan Freedman Kashmir Hill ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Good programmers need to create code that efficiently solves problems, using various methods. A ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

What if machines could not only learn but also teach themselves to become better with each iteration? This isn’t the plot of a sci-fi movie—it’s the reality unfolding in artificial intelligence ...